Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 12/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 12/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5079264 | 0.91 | NFKB1 (0.61) | NFKB1NFKB2RELAHTR2CKIT | |
| SCHEMBL3072684 | 0.79 | ENPP1 (0.55) | KIT | |
| SCHEMBL5262815 | 0.79 | NFKB1 (0.52) | NFKB1NFKB2RELAHTR2CKIT | |
| SCHEMBL28855745 | 0.77 | HTR2C (0.55) | NFKB1NFKB2RELAHTR2CKIT | |
| SCHEMBL2139019 | 0.76 | NFKB1 (0.59) | NFKB1NFKB2RELAHTR2CKIT | |
| SCHEMBL13908867 | 0.76 | NFKB1 (0.81) | NFKB1NFKB2RELAHTR2CKIT | |
| SCHEMBL16766424 | 0.75 | NFKB1 (0.70) | NFKB1NFKB2RELAHTR2CKIT | |
| SCHEMBL2136321 | 0.75 | NFKB1 (0.89) | NFKB1NFKB2RELAHTR2CKIT | |
| SCHEMBL2139370 | 0.75 | NFKB1 (1.00) | NFKB1NFKB2RELAHTR2CKIT | |
| SCHEMBL31337089 | 0.74 | HTR2C (0.65) | HTR2CKITADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20090304632-A1 | HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKB2, NFKBIA, NFRKB | NFKB1 4/4885NFKB2 1/4885RELA 6/4885 |
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | NFKB2, NFKBIA, NFRKB | NFKB1 4/4885NFKB2 1/4885RELA 6/4885 |
| US-20090304632-A1 | HETEROCYCLIC NF-kB INHIBITORS | NFKBIA, NFKB2, IKBKB | NFKB1 5/4885NFKB2 2/4885RELA 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.